Form 4: Virios Therapeutics Director, David R. Keefer, Acquires Stock Options
SEC Form 4 Filing
Director David R. Keefer acquired stock options in Virios Therapeutics, Inc. on February 26, 2024.
Summary
- On February 26, 2024, David R. Keefer, a director of Virios Therapeutics, Inc., acquired 4,709 stock options with an exercise price of $0.357.
- These options vest 100% on February 26, 2025, and expire on February 26, 2034.
- Following the transaction, Keefer directly owns 4,709 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance.
Positives
- The acquisition of stock options by a director may indicate confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It's common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders, as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of transaction: David R. Keefer acquired stock options. |
| 02/26/2025 | Vesting date: Stock options vest 100%. |
| 02/26/2034 | Expiration date: Stock options expire. |
| 02/28/2024 | Date of signature on the Form 4 filing. |
Keywords
stock options, Form 4, Virios Therapeutics, director, Keefer, VIRI, acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.